Loading
Boston Scientific Corp Stock: price and insider trades · United States
4 insiders bought €8.2M of shares over the last 90 days, the latest filed 26 Aug 2026.
Boston Scientific Corp: what insiders have been doing
Headquartered in Marlborough, United States, Boston Scientific Corp belongs to the Healthcare & Pharma sector and traces its origins to 1979. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 56 filings were filed, from 14 insiders.
Purchases and sales both appear in the filings: 10 purchases (5 insiders, €8.7M) and 7 sales (3 insiders, €8.1M). Netting one side against the other leaves €646k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €7.8M by Mahoney Michael F, published on 5 August 2026, equal to 0.014% of the market capitalisation. Among those who bought: 4 senior executives and 1 chief executive.
In all, 9 purchases were made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 53 days ago, on 26 August 2026. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
With 56 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Since 2016, the database holds 13 purchases and 106 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 20.07 bn USD and net income at 2.89 bn USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
557
Thresholds
n/a
Buy Volume
€10M
13 ops. · all time
Sell Volume
€90M
106 ops. · all time
Who traded when
BuySaleDavid C. Habiger5 buys
Edward J. Ludwig2 buys3 sales
Ellen M. Zane4 sales
Joseph Michael Fitzgerald1 buy3 sales
Vance R. Brown4 sales
Jeffrey B. Mirviss2 sales
+8 other insiders
Since the insiders bought
- -5.4%Entry US$46.67 · Close 15 Oct 2026 US$44.14
- -12.5%Entry US$50.46 · Close 15 Oct 2026 US$44.14
- -10.5%Entry US$49.30 · Close 15 Oct 2026 US$44.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Boston Scientific Corp Buy (bullish), based on 29 analysts. Average price target: US$59.55.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,309 of 24,161 companies
63.5
score / 100
Value55
Quality72
FCF yld5.3%
Earn yld4.5%
EV/EBITDA14.8x
ROE15%
Gross mgn69%
Net mgn14%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$43.31
Analyst consensus
29 analystsBuy
US$44.00Target US$59.55(+38%)US$94.00
Income statement
RevenueUS$20.1B
Gross profitUS$13.9B69% margin
EBITDAUS$5.1B25% margin
Net incomeUS$2.9B17.5% margin
Valuation
PER (trailing)17.5x
PER (forward)12.8x
P/Book2.5x
Beta0.58
Balance sheet & cash
Market capUS$62.8B
Total debtUS$11.4B
Free Cash FlowUS$3.4B
Debt / Equity50%
Profitability & ownership
ROE15.3%
ROA6.2%
% insiders0.3%
% institutions95.3%
Last declaration on 3 September 2026
Declarations557 total
567 shares@ US$48.370.0000% mcap100.0% of flowCommon StockSEC:0001225208-26-007620:1
1,171 shares0Common StockSEC:0001225208-26-007620:0
2,040 shares@ US$49.21950.0002% mcap100.0% of flowCommon StockSEC:0001225208-26-007337:0
Canonical exit: 23 Nov 2026 (T+90)
2,930 shares@ US$51.190.0002% mcap17.3% of flowCommon StockSEC:0001225208-26-007084:0
9,908 shares@ US$50.460.0008% mcap46.9% of flowCommon StockSEC:0001225208-26-007062:0
2,100 shares@ US$47.5890.0002% mcap24.6% of flowCommon StockSEC:0001225208-26-007031:0
Canonical exit: 3 Nov 2026 (T+90)
186,240 shares@ US$48.33230.014% mcap12.9% of flowCommon StockSEC:0001225208-26-006950:0
Canonical exit: 1 Nov 2026 (T+90)
22,119 shares@ US$48.430.0017% mcap1.5% of flowCommon StockSEC:0001225208-26-006950:1
1,042 shares@ US$48.06550.0001% mcap12.3% of flowCommon StockSEC:0001225208-26-006951:0
Canonical exit: 1 Nov 2026 (T+90)
140 shares@ US$48.58790.0000% mcap1.7% of flowCommon StockSEC:0001225208-26-006951:1
Canonical exit: 2 Nov 2026 (T+90)
5,000 shares@ US$45.47990.0004% mcap11.0% of flowCommon StockSEC:0001225208-26-006882:0
Canonical exit: 29 Oct 2026 (T+90)
64,198 shares@ US$46.730.0047% mcap7.5% of flowCommon StockSEC:0001225208-26-006881:0
2,087 sharesCommon StockSEC:0001225208-26-006362:0
1,010 sharesCommon StockSEC:0001225208-26-006362:1
386,755 shares0Common StockSEC:0001225208-26-005670:0
2,250 shares@ US$55.91950.0002% mcap30.7% of flowCommon StockSEC:0001225208-26-005546:1
Canonical exit: 18 Aug 2026 (T+90)
3,580 shares@ US$56.680.0003% mcap9.7% of flowCommon StockSEC:0001225208-26-005547:0
Canonical exit: 18 Aug 2026 (T+90)
1,770 shares@ US$56.490.0001% mcap100.0% of flowCommon StockSEC:0001225208-26-005548:0
Canonical exit: 18 Aug 2026 (T+90)
2,200 shares@ US$56.94510.0002% mcap30.6% of flowCommon StockSEC:0001225208-26-005546:0
Canonical exit: 17 Aug 2026 (T+90)
24 shares0Common StockSEC:0001225208-26-003179:0
556 shares0Common StockSEC:0001225208-26-003178:0
838 shares0Common StockSEC:0001225208-26-003014:0
6,851 shares@ US$75.768.0% of flowCommon StockSEC:0001225208-26-002794:0
1,413 shares0Common StockSEC:0001225208-26-002139:0
500 shares0Common StockSEC:0001225208-26-002137:0
25 of 557 declarations
About Boston Scientific Corp
Boston Scientific Corp. is a global medical technology company listed in the United States on the NYSE under the ticker BSX. For French-speaking investors, it is a large-cap healthcare name exposed to structurally attractive end markets driven by aging populations, the rise of chronic disease, and continuous innovation in minimally invasive care. The company was founded in 1979 in Watertown, Massachusetts, and today has its world headquarters in Marlborough, Massachusetts, in the United States. Its corporate identity was built around interventional medicine, with a strategy focused on differentiated technologies and clinical niches where product innovation, physician adoption, and regulatory clearance create meaningful barriers to entry. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai))
Boston Scientific reports through two major segments: MedSurg and Cardiovascular. Its portfolio spans electrophysiology and cardiac rhythm management, left atrial appendage closure, coronary and peripheral interventions, endoscopy, urology, and neuromodulation, along with certain minimally invasive surgical solutions. This diversification gives the company a resilient profile while also supporting above-average growth through a mix of mature franchises and newer platforms. Key product families include WATCHMAN, FARAPULSE, EKOS, EMBLEM MRI S-ICD, and a broad range of endoscopy and urology systems. ([news.bostonscientific.com](https://news.bostonscientific.com/interested-in-our-q4-2024-financial-results?utm_source=openai))
Read moreShow less
From a competitive standpoint, Boston Scientific ranks among the leading global players in implantable and interventional medical devices, competing with companies such as Medtronic, Abbott, Johnson & Johnson, and Edwards depending on the end market. Its edge comes from portfolio expansion, a strong innovation engine, and disciplined commercial execution across hospitals, electrophysiologists, interventional cardiologists, gastroenterologists, and urologists. The group also has a broad international footprint, with sales across multiple geographies and manufacturing and assembly capacity spread over several sites worldwide. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai))
Recent developments reinforce that thesis. Boston Scientific reported first-quarter 2026 net sales of $5.203 billion, up 11.6% year over year, and fourth-quarter 2025 sales of $5.286 billion, with full-year 2025 revenue reaching $20.074 billion. The company also released positive clinical data for FARAPULSE and WATCHMAN, received FDA approvals and clearances for several products, and announced acquisitions including Bolt Medical. For investors, BSX remains a high-quality Healthcare / Pharma stock combining organic growth, innovation, and portfolio leverage on a liquid, closely followed U.S. equity market. ([news.bostonscientific.com](https://news.bostonscientific.com/2026-04-22-Boston-Scientific-announces-results-for-first-quarter-2026?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
